FDA grants priority review to Pfizer cancer treatment.
+ Technology/Innovation
Jamie Barrand | Dec 10, 2015

FDA grants priority review to Pfizer cancer treatment

Priority review has been granted by the U.S. Food and Drug Administration (FDA) for Xalkori (crizotinib), which is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).

Xalkori is a product of Pfizer Inc. The therapy was designated by the FDA earlier this year as a breakthrough therapy. Currently, there are no biomarker-driven treatments like Xalkori on the market.

FDA action is expected to take place by April 2016.

“The development of Xalkori in a subgroup of patients is an example of the capability of precision medicine to identify treatments for patients whose tumors contain rare genetic mutations, such as ROS1-positive metastatic NSCLC," Dr. Mace Rothenberg, chief medical officer at Pfizer Oncology, said.

For more information, log on to www.xalkori.com.

Organizations in this story

+ Pfizer

More News